A New Sildenafil Oral Film in Patients With Erectile Dysfunction

Erectile Dysfunction Clinical Trial

Official title:

A Multi-center, Prospective, Randomized, Double-blind, Flexible-dose, Placebo-controlled, Parallel Group Clinical Trial of Sildenafil Oral Film 25 mg, 50 mg, 75 mg and 100 mg for the Treatment of Erectile Dysfunction (ED)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05490680
• Other study ID #: 20US-SDF15
• Status: Recruiting
• Phase: Phase 3
• Start date: January 26, 2024
• Est. completion date: December 2024

Study information

• Verified date: March 2024
• Source: IBSA Institut Biochimique SA
• Contact: Valeria Frangione, PhD
• Phone: +41583600000
• Email: Valeria.Frangione[@]ibsa.ch
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a Phase III, prospective, interventional, multi-center, randomized, double-blind, flexible-dose, placebo-controlled, parallel group clinical study required by FDA to demonstrate the efficacy and safety of Sildenafil oral film 25 mg, 50 mg, 75 mg and 100 mg as compared to placebo in approximately 488 men clinically diagnosed with erectile dysfunction (ED).

Description:

The study will consist of a Screening Visit (Visit 0) followed by a 4-week run-in period without treatment and by a Randomization Visit (Visit 1) for the subjects who were compliant in pre-treatment phase. After randomization, the subject will start a 12-week, double-blind, flexible-dose, treatment phase comprising 4 at Site Visits performed 2 weeks after starting the treatment (Visit 2), after additional 2 weeks (Visit 3) and every 4 weeks (Visits 4 and 5) until the End of Study.

The target population for this study is men with ED, including 30-35% of geriatric ED subjects. Subjects < 65 years of age will be randomized to receive the Sildenafil/Placebo oral film at 50 mg dose. Subjects ≥ 65 years of age will be randomized to receive the Sildenafil/Placebo oral film at 25 mg dose. The study foresees a flexible-dose regimen and the starting dosage can be increased to 50 mg (for subjects ≥ 65 years of age), 75 mg or 100 mg dosage, or decreased.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 488
• Est. completion date: December 2024
• Est. primary completion date: October 2024
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Heterosexual male subjects aged =18 years;

• Confirmed clinical diagnosis of ED for at least 6 months;

• Involved in a continuous sexual relationship with their partner for at least 3 months.

• Able and willing to provide voluntary written informed consent

Exclusion Criteria:

• Currently suffering from any oromucosal condition or recent oral surgery that could interfere with the study drug;

• Any significant cardiovascular abnormality;

• Patients = 65 years with any degree of hepatic impairment or severe renal impairment or any significant pulmonary, gastrointestinal, hematological, endocrinal, metabolic or neurological disorder;

• Patients < 65 years with severe hepatic impairment;

• Any presence of chronic indwelling urethral catheterization or penile anatomical abnormalities that would significantly impair EF;

• Any history of Peyronie's disease; or who have conditions which may predispose them to priapism;

• Any history or comorbidity of hypoactive sexual desire disorder, premature ejaculation or other ejaculatory disorders or radical prostatectomy;

• Any history of severe/uncontrolled diabetes or radical prostatectomy or spinal cord injury

• Hypersensitivity to Sildenafil or to any of the excipients of the oral film, or idiosyncratic reactions to other PDE5 inhibitors;

• Any history of migraine;

• Any history of complete unresponsiveness to PDE5 inhibitor treatment or significant side-effects with PDE5 inhibitor;

• Subjects with or with history of severe vision impairment, temporary visual disturbances (blurred vision, increased light sensitivity and color change), retinitis pigmentosa, Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) or any optic neuropathy;

• Subjects taking a strong CYP3A4 inhibitor(s);

• During the course of the study, subjects are not allowed to take any prescription, over-the-counter, herbal, or naturopathic products for "male enhancement" or the treatment of ED;

• During the course of the study, subjects are not allowed to take any form of nitric oxide donors such as organic nitrates or organic nitrites either regularly and/or intermittently, and guanylate cyclase (GC) stimulators;

• Patients must be stable on therapy with Alpha-blockers or Amlodipine at inclusion and already taking a PDE5 inhibitor without any safety concern prior to initiating the study (i.e., no history of significant side-effects with co-administration of PDE5 inhibitors);

• Subjects known to abuse alcohol or drugs that could interfere with the patient's safety or study compliance

• Subjects who are illiterate or are unable to understand how to use eDiary and complete the questionnaires

Related Conditions & MeSH terms

• Erectile Dysfunction

Intervention

Drug:
• Sildenafil Oral Film 25 mg, 50 mg, 75 mg or 100 mg
Sildenafil Oral Film containing 25 mg, 50 mg, 75 mg or 100 mg sildenafil as citrate, flexible-dose
• Placebo
Placebo Oral Film

Locations

Country	Name	City	State
United States	G & L Research LLC.	Foley	Alabama
United States	Innovation Medical Group LLC (Endo Care of South Florida)	Fort Lauderdale	Florida
United States	AccuMed Research Associates	Garden City	New York
United States	Medical Affiliated Research Center	Huntsville	Alabama
United States	Alliance for Multispeciaty Research, LLC	Knoxville	Tennessee
United States	Alliance for Multispecialty Research, LLC	Las Vegas	Nevada
United States	Arkansas Urology Research Center	Little Rock	Arkansas
United States	Urology Group of Southern California	Los Angeles	California
United States	Clintex Research Group	Miami	Florida
United States	Coral Research Clinic	Miami	Florida
United States	Tri Valley Urology Medical Group	Murrieta	California
United States	Harmony Clinical Research	North Miami Beach	Florida
United States	Innovation Clinical Trials: Medical Reseach Center	Palmetto Bay	Florida
United States	Virginia Urology	Richmond	Virginia
United States	Rochester Clinical Research, Inc	Rochester	New York
United States	Mt. Olympus Medical Research Group, LLC	Sugar Land	Texas
United States	Precision Clinical Research, LLC	Sunrise	Florida
United States	Tranquil Clinical and Research Consulting Services, LLC	Webster	Texas

Sponsors (1)

Lead Sponsor	Collaborator
IBSA Institut Biochimique SA

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Exploratory efficacy of Sildenafil oral film compared to placebo - attempts	Number of attempts for sexual intercourse	Up to 12 weeks of treatment
Other	Exploratory efficacy of Sildenafil oral film compared to placebo - overall treatment satisfaction	Mean treatment satisfaction as assessed by Overall Treatment Satisfaction score on a 5-point scale (4=excellent; 3=good; 2=fair; 1=poor; 0=none)	Up to 12 weeks of treatment
Other	Exploratory efficacy of Sildenafil oral film compared to placebo - GAQ	Proportion of subject responses to Global Assessment Questionnaire (GAQ) consisting of 2 questions (Yes or No): Question 1 'Has the treatment you have been taking improved your erectile function?' and if necessary, Question 2 'If yes, has the treatment improved your ability to engage in sexual activity?'.	Up to 12 weeks of treatment
Other	Exploratory efficacy of Sildenafil oral film compared to placebo - drug product palatability	Subjective measures of the Drug Product Palatability consisting of 5 specific questions: "1. Rate the oral sensation/mouthfeel of the drug product"; "2. Rate the taste of the drug product"; "3. How strong is the taste?"; "4. Rate the aftertaste of the drug product"; and "5. How strong is the aftertaste?". For questions 1, 2, and 4, the range of responses is: "very unpleasant, unpleasant, no sensation/mouthfeel, pleasant, very pleasant." For questions 3 and 5, the range of responses is: "very strong, strong, moderate, mild, no taste".	Up to 12 weeks of treatment
Primary	Safety of Sildenafil doses versus placebo	Safety of Sildenafil doses versus placebo, i.e., the proportion of subjects with at least one Treatment Emergent Adverse Events (TEAEs) of Special Interest ("Headache" or "Dizziness")	12 weeks of treatment
Primary	Efficacy of Sildenafil doses versus placebo - IIEF-EF	Efficacy of Sildenafil oral film versus placebo evaluated using co-primary efficacy endpoint from the change in Erectile Function (EF) domain of the International Index for Erectile Function (IIEF) questionnaire	Baseline to the end of the 12-week treatment period
Primary	Efficacy of Sildenafil doses versus placebo - SEP Question 2	Efficacy of Sildenafil oral film versus placebo evaluated using co-primary efficacy endpoint from the change in percentage of "yes" responses to Sexual Encounter Profile (SEP) Question 2	Between the 4-week pre-treatment period and the end of the 12-week treatment period
Primary	Efficacy of Sildenafil doses versus placebo - SEP Question 3	Efficacy of Sildenafil oral film versus placebo evaluated using co-primary efficacy endpoint from the change in percentage of "yes" responses to SEP Question 3	Between the 4-week pre-treatment period and the end of the 12-week treatment period
Secondary	Safety TEAE of special interest - headache	The incidence of TEAEs of Special Interest of headache	Over 12 weeks of treatment as compared to placebo
Secondary	Safety TEAE of special interest - dizziness	The incidence of TEAEs of Special Interest of dizziness	Over 12 weeks of treatment as compared to placebo
Secondary	Safety TEAE of vasomotor drug effects	The incidence of TEAEs that may be suggestive of vasomotor drug effects and the proportion of subjects with at least one of these TEAEs	Over 12 weeks of treatment as compared to placebo;